Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its vaccine adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.

Leveraging over 80 years of expertise, Croda Pharma collaborates with vaccine manufacturers to tailor and develop optimal vaccine formulations using their excipients, lipids, and adjuvants. With an established portfolio of GMP and high-performance adjuvants, including Alhydrogel™ and Adjuphos™, the company also assists vaccine developers through lipids for the delivery of nucleic acid-based therapeutics. Their experts develop and manufacture high purity and innovative lipids to solve the stability and delivery issues associated with mRNA delivery and next-generation vaccines and therapeutics

Croda Pharma is on a mission to support the development of the novel adjuvants of tomorrow. The company is committed to making these adjuvants available for preclinical and clinical R&D programs, with both industrial and academic partners.

Croda Pharma continues to expand its offering in innovative speciality excipients, vaccine adjuvant systems, and lipids. By enabling over 250 ongoing clinical projects, targeting a range of therapeutic areas including oncology, malaria, HIV, and diabetes, they strive to empower biopharma and improve lives across the globe. As a part of Croda, the company is dedicated to being the most sustainable supplier of innovative ingredients, becoming Climate, Land, and People Positive by 2030.

Last updated : June 28, 2023